Status:

COMPLETED

Glivec in Ph Positive Lymphoblastic Leukemia

Lead Sponsor:

PETHEMA Foundation

Conditions:

Acute Lymphoblastic Leukemia

Cromosome Philadelphia Positive

Eligibility:

All Genders

Up to 65 years

Phase:

PHASE2

Brief Summary

% positive Ph LLA with RC alter the Glivec and induction chemotherapy treatment

Detailed Description

Pilot phase II clinical trial, prospective, multicentric and opened

Eligibility Criteria

Inclusion

  • New diagnosis LLA Ph+ (BCR/ABL) patients ≤ 65 years old
  • Fertile age women must do a pregnancy test in the 7 days previous at the beginning of clinical trial medication
  • Performance status 0-2 (Appendix B); Is allowed performance status \> 2 because of LLA
  • Patients without organ alteration: hepatic function: global bilirubin, AST, ALT, gamma-GT and alkaline phosphatase less than 2 times LSN; renal function: Creatinine \< 1,5 mg/dl o Clearance creatinine \> 60 ml/min; anormal renal function caused by LLA ; normal heart function (Appendix B): FEV \> 50%; No Chronic respiratory illness. If the anormal values are secondary of the experimental illness the investigator can decide himself if the patient can be included at the clinical trial.
  • Negative HIV serology
  • Written, oral or with witness informed consent. In patients \< 18 years old must be signed written and legal representative informed consent.
  • No experimental chemotherapy or other experimental treatment. Allowed to begin induction chemotherapy from the diagnosis to confirm Ph. No major surgical process in the previous 14 days of the treatment Start.

Exclusion

  • Other LLA variability
  • Previous history of coronary valvular, hypertensive cardiopathy illness
  • Chronic hepatic illness
  • Chronic respiratory insufficiency
  • Renal insufficiency not caused by LLA
  • Severe neurological problems not caused by LLA
  • Severe affection of the performance status (grade 3-4 OMS gradation) not caused by LLA
  • Pregnancy and women
  • Blastic crisis LMC

Key Trial Info

Start Date :

June 1 2002

Trial Type :

INTERVENTIONAL

End Date :

October 1 2007

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT00388895

Start Date

June 1 2002

End Date

October 1 2007

Last Update

November 19 2008

Active Locations (28)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (28 locations)

1

Hospital General de Alicante

Alicante, Alicante, Spain

2

Hospital "Duran I Reynals"

Barcelona, Barcelona, Spain

3

Hospital "Santa Creu i Sant Pau"

Barcelona, Barcelona, Spain

4

Hospital Clínico y Provincial de Barcelona

Barcelona, Barcelona, Spain